Lancet: Second-line drug selection for patients of all ages with refractory persistent epilepsy

For children with incurable or persistent epilepsy, the pathophysiological characteristics are similar to those of adults, but differences in potential etiology and pharmacodynamics may lead to differences in therapeutic responsesRecently, researchers examined the effects of receiving sodium zoerace, phosphorayltoyin and 2-propylene-propyl hydrochloric acid in children with refractory epilepsythe study was conducted in 58 medical centers in the United States, aged 2 years or older, and was followed by children with systemic convulsions that lasted more than 5 minutes after receiving adequate treatmentPatients were randomly accepted by age group (18- 65 years of age, and .65 years) with sodium zoerace, phosphorus benzene, or 2-propylene-based sodiumThe main results of the study were that within one hour of the onset of the drug infusion, there were no clinically visible seizures, improved awareness, and no additional anti-epileptic drugs were requiredThe main safety outcome is life-threatening hypotension or arrhythmiastudies recruited 462 patients, including 225 children (age 18), 186 adults (18-65 years) and 51 older persons (age 65)175 patients (38%) received zoeaceitan at random, 142 (31%) received phosphate benzene, and 145 (31%) received 2-propylene-based sodium hydrochloriteThe baseline characteristics were similar, with 52 per cent of children in the left ethyl lasitan treatment group, 44 per cent of adults and 37 per cent of the elderly reaching the main endpoint; There was no difference in the efficacy or primary safety of drugs in all age groupsThere was no significant difference in the safety results of secondary drugs in all age groups except for the intubation of the children's tracheastudies found that for children, adults and elderly patients with persistent epilepsy with benzodiazepines, the effect was similar after treatment with zoerace, phosphate totonic or sodium 2-propylene hydrochloride, and about half of the patients experienced improved symptomsAll three drugs are available as the preferred second-line drugs for the persistent state of benzodiazepines, refractory epilepsy